Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Trailblazing precision medicine in Europe : A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

Stenzinger, Albrecht ; Edsjö, Anders LU ; Ploeger, Carolin ; Friedman, Mikaela ; Fröhling, Stefan ; Wirta, Valtteri ; Seufferlein, Thomas ; Botling, Johan ; Duyster, Justus and Akhras, Michael , et al. (2022) In Seminars in Cancer Biology 84. p.242-254
Abstract

Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to... (More)

Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cancer, Clinical trials, Molecular profiling, Personalized medicine, Precision medicine
in
Seminars in Cancer Biology
volume
84
pages
242 - 254
publisher
Academic Press
external identifiers
  • scopus:85111382323
  • pmid:34033893
ISSN
1044-579X
DOI
10.1016/j.semcancer.2021.05.026
language
English
LU publication?
yes
additional info
Funding Information: GMS support was provided by the Swedish Innovation Agency Vinnova , participating University Hospitals and Medical faculties of the GMS seven nodes , and strategic innovation agency SweLife (part of Vinnova) . The ZPMs are supported by the Ministry of Social Affairs and Integration Baden-Wuerttemberg as well as the German Cancer Aid . We are grateful to Yvonne Reichelt for expert editorial assistance. Funding Information: To achieve the aim of generating large clinico-molecular datasets across centers, which will monitor outcome data and inform therapy recommendations, the non-commercial central data sharing platform bwHealthCloud has been established by the ZPMs under the lead of the University Hospital Tübingen. It allows highly protected, decentralized data exchange in a standardized manner across the institutions involved in ZPM. For efficient and sustainable sharing, processing and storing of data and to facilitate the automated and standardized collection of data from different sites, the ZPMs have developed and agreed on common pivotal data sets. These data sets contain a specified set and format of clinical data, molecular data, pathological data, medical imaging data, therapy recommendations, and follow-up data. The outcome data of the bwHealthCloud, which will be regularly evaluated and monitored by academic stakeholders and payers, will inform molecular boards and future clinical trials. The technology set-up is supported by the Ministry for Social Affairs and Integration Baden-Wuerttemberg. As a next step, regional partner sites will be integrated and further aligned with other consortia efforts including the German medical informatics initiative (MI-I) launched and funded by the German Federal Ministry of Education and Research (BMBF). Funding Information: AE: research grants: Amgen and AstraZeneca, honoraria: Amgen, AstraZeneca, Bayer, Diaceutics, Roche. RR: honoraria: AbbVie, AstraZeneca, Illumina, Jansen, Roche, advisory boards: AbbVie, Illumina. SF: research grants: AstraZeneca, Boehringer Ingelheim, Pfizer, PharmaMar, Roche, honoraria: Amgen, Eli Lilly, PharmaMar, Roche, advisory boards: Bayer, Illumina, Roche. AS: advisory board/speaker’s bureau: AstraZeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher. Grants: Bayer, BMS, Chugai. PS: speaker’s bureau: AstraZeneca, Incyte, Janssen, advisory boards: BMS, MSD, AstraZeneca, Roche. TF: co-founder and board member: Qlucore AB, Cantargia AB, consultancy: Illumina Inc. VW: honoraria: Illumina. All other authors declared no conflict of interest. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
id
d87717ac-42ea-4b73-8306-a38461dfed6f
date added to LUP
2021-08-31 16:07:54
date last changed
2022-08-11 23:39:23
@article{d87717ac-42ea-4b73-8306-a38461dfed6f,
  abstract     = {{<p>Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.</p>}},
  author       = {{Stenzinger, Albrecht and Edsjö, Anders and Ploeger, Carolin and Friedman, Mikaela and Fröhling, Stefan and Wirta, Valtteri and Seufferlein, Thomas and Botling, Johan and Duyster, Justus and Akhras, Michael and Thimme, Robert and Fioretos, Thoas and Bitzer, Michael and Cavelier, Lucia and Schirmacher, Peter and Malek, Nisar and Rosenquist, Richard}},
  issn         = {{1044-579X}},
  keywords     = {{Cancer; Clinical trials; Molecular profiling; Personalized medicine; Precision medicine}},
  language     = {{eng}},
  pages        = {{242--254}},
  publisher    = {{Academic Press}},
  series       = {{Seminars in Cancer Biology}},
  title        = {{Trailblazing precision medicine in Europe : A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany}},
  url          = {{http://dx.doi.org/10.1016/j.semcancer.2021.05.026}},
  doi          = {{10.1016/j.semcancer.2021.05.026}},
  volume       = {{84}},
  year         = {{2022}},
}